Terms: = Bone cancer AND NPM1, NPM, 4869, ENSG00000181163, P06748, B23, MGC104254 AND Treatment
61 results:
1. Clinical and genetic characteristics predict outcomes of acute myeloid leukemia patients with FLT3 mutations receiving venetoclax-based therapy.
Weng G; Huang J; An N; Zhang Y; Yu G; Sun Z; Lin D; Deng L; Liang X; Xiao J; Zhang H; Guo Z; He X; Jin H; Liu Q; Du X
Cancer Med; 2024 Jan; 13(2):e6885. PubMed ID: 38334500
[TBL] [Abstract] [Full Text] [Related]
2. Understanding differential technologies for detection of MRD and how to incorporate into clinical practice.
Cloos J; Ngai LL; Heuser M
Hematology Am Soc Hematol Educ Program; 2023 Dec; 2023(1):682-690. PubMed ID: 38066915
[TBL] [Abstract] [Full Text] [Related]
3. Immune Surveillance of Acute Myeloid Leukemia Is Mediated by HLA-Presented Antigens on Leukemia Progenitor Cells.
Nelde A; Schuster H; Heitmann JS; Bauer J; Maringer Y; Zwick M; Volkmer JP; Chen JY; Stanger AMP; Lehmann A; Appiah B; Märklin M; Rücker-Braun E; Salih HR; Roerden M; Schroeder SM; Häring MF; Schlosser A; Schetelig J; Schmitz M; Boerries M; Köhler N; Lengerke C; Majeti R; Weissman IL; Rammensee HG; Walz JS
Blood Cancer Discov; 2023 Nov; 4(6):468-489. PubMed ID: 37847741
[TBL] [Abstract] [Full Text] [Related]
4. Molecular MRD is strongly prognostic in patients with npm1-mutated AML receiving venetoclax-based nonintensive therapy.
Othman J; Tiong IS; O'Nions J; Dennis M; Mokretar K; Ivey A; Austin M; Latif AL; Amer M; Chan WY; Crawley C; Crolla F; Cross J; Dang R; Elliot J; Fong CY; Galli S; Gallipoli P; Hogan F; Kalkur P; Khan A; Krishnamurthy P; Laurie J; Loo S; Marshall S; Mehta P; Murthy V; Nagumantry S; Pillai S; Potter N; Sellar R; Taylor T; Zhao R; Russell NH; Wei AH; Dillon R
Blood; 2024 Jan; 143(4):336-341. PubMed ID: 37647641
[TBL] [Abstract] [Full Text] [Related]
5. Molecular and clinical significance of FLT3, npm1, DNMT3A and TP53 mutations in acute myeloid leukemia patients.
Ali AM; Salih GF
Mol Biol Rep; 2023 Oct; 50(10):8035-8048. PubMed ID: 37540457
[TBL] [Abstract] [Full Text] [Related]
6. Phenotypic clues that predict underlying cytogenetic/genetic abnormalities in myeloid malignancies: A contemporary review.
Stone M; Lilley CM; Tang G; Loghavi S; Mirza KM
Cytopathology; 2023 Nov; 34(6):530-541. PubMed ID: 37522274
[TBL] [Abstract] [Full Text] [Related]
7. A Single-Cell Taxonomy Predicts Inflammatory Niche Remodeling to Drive Tissue Failure and Outcome in Human AML.
Chen L; Pronk E; van Dijk C; Bian Y; Feyen J; van Tienhoven T; Yildirim M; Pisterzi P; de Jong MME; Bastidas A; Hoogenboezem RM; Wevers C; Bindels EM; Löwenberg B; Cupedo T; Sanders MA; Raaijmakers MHGP
Blood Cancer Discov; 2023 Sep; 4(5):394-417. PubMed ID: 37470778
[TBL] [Abstract] [Full Text] [Related]
8. Hypoplastic form of myelodysplastic neoplasm.
Votavová H; Lenertová Z; Votava T; Beličková M
Klin Onkol; 2023; 36(3):206-214. PubMed ID: 37353349
[TBL] [Abstract] [Full Text] [Related]
9. Immunophenotypical profiling of myeloid neoplasms with erythroid predominance using mass cytometry (CyTOF).
Maag AH; Swanton H; Kull M; Vegi NM; Feuring M
Cytometry A; 2023 Jul; 103(7):551-562. PubMed ID: 36647792
[TBL] [Abstract] [Full Text] [Related]
10. The role of npm1 alternative splicing in patients with chronic lymphocytic leukemia.
Szelest M; Masternak M; Zając M; Chojnacki M; Skórka K; Zaleska J; Karczmarczyk A; Stasiak G; Wawrzyniak E; Kotkowska A; Siemieniuk-Ryś M; Purkot J; Subocz E; Cichocka E; Tomczak W; Zawirska D; Giannopoulos K
PLoS One; 2022; 17(10):e0276674. PubMed ID: 36282861
[TBL] [Abstract] [Full Text] [Related]
11. The International Consensus Classification of acute myeloid leukemia.
Weinberg OK; Porwit A; Orazi A; Hasserjian RP; Foucar K; Duncavage EJ; Arber DA
Virchows Arch; 2023 Jan; 482(1):27-37. PubMed ID: 36264379
[TBL] [Abstract] [Full Text] [Related]
12. Molecular predictors of immunophenotypic measurable residual disease clearance in acute myeloid leukemia.
Stahl M; Derkach A; Farnoud N; Bewersdorf JP; Robinson T; Famulare C; Cho C; Devlin S; Menghrajani K; Patel MA; Cai SF; Miles LA; Bowman RL; Geyer MB; Dunbar A; Epstein-Peterson ZD; McGovern E; Schulman J; Glass JL; Taylor J; Viny AD; Stein EM; Getta B; Arcila ME; Gao Q; Barker J; Shaffer BC; Papadopoulos EB; Gyurkocza B; Perales MA; Abdel-Wahab O; Levine RL; Giralt SA; Zhang Y; Xiao W; Pai N; Papaemmanuil E; Tallman MS; Roshal M; Goldberg AD
Am J Hematol; 2023 Jan; 98(1):79-89. PubMed ID: 36251406
[TBL] [Abstract] [Full Text] [Related]
13. Monitoring Minimal Residual Disease in RUNX1-Mutated Acute Myeloid Leukemia.
Nachmias B; Krichevsky S; Filon D; Even-Or E; Gatt ME; Saban R; Avni B; Grisariu S; Aumann S; Vainstein V
Acta Haematol; 2022; 145(6):642-649. PubMed ID: 35933982
[TBL] [Abstract] [Full Text] [Related]
14. Clinical Significance of MAP-7 and FOXC1 in Egyptian Acute Myeloid Leukemia Patients.
Nabawy SM; Refaat LA; Naser-Aldin HM; Rashed RA
Asian Pac J Cancer Prev; 2022 May; 23(5):1619-1626. PubMed ID: 35633546
[TBL] [Abstract] [Full Text] [Related]
15. [Analysis of clinical significance and prognostic impact of TET2 single nucleotide polymorphism I1762V in patients with acute myeloid leukemia].
Li YW; Guo Z; Wang LL; Zhou L; Lyu XD; Song YP
Zhonghua Xue Ye Xue Za Zhi; 2022 Mar; 43(3):241-246. PubMed ID: 35405783
[No Abstract] [Full Text] [Related]
16. npm1-mutation-based measurable residual disease assessment after completion of two courses of post-remission therapy is a valuable clinical predictor of the prognosis of acute myeloid leukemia.
Marumo A; Wakita S; Morita K; Oh I; Kako S; Toya T; Najima Y; Doki N; Kanda J; Kuroda J; Mori S; Satake A; Usuki K; Uoshima N; Kobayashi Y; Kawata E; Nagao Y; Shono K; Shibusawa M; Tadokoro J; Hagihara M; Uchiyama H; Kubota Y; Kimura S; Motomura S; Hashimoto A; Muto H; Sato E; Ogata M; Mitsuhashi K; Ando J; Date K; Fujiwara Y; Terada K; Yui S; Arai K; Kitano T; Miyata M; Ohashi K; Kanda Y; Yamaguchi H
Int J Hematol; 2022 Aug; 116(2):199-214. PubMed ID: 35377134
[TBL] [Abstract] [Full Text] [Related]
17. Complete bone Marrow Necrosis with Charcot-Leyden Crystals Caused by Myeloid Neoplasm with Mutated npm1 and TET2.
Saito K; Sato T; Notohara K; Nannya Y; Ogawa S; Ueda Y
Intern Med; 2022 Nov; 61(21):3265-3269. PubMed ID: 35185048
[TBL] [Abstract] [Full Text] [Related]
18. Impact of FLT3 Mutation on Outcomes after Venetoclax and Azacitidine for Patients with treatment-Naïve Acute Myeloid Leukemia.
Konopleva M; Thirman MJ; Pratz KW; Garcia JS; Recher C; Pullarkat V; Kantarjian HM; DiNardo CD; Dail M; Duan Y; Chyla B; Potluri J; Miller CL; Wei AH
Clin Cancer Res; 2022 Jul; 28(13):2744-2752. PubMed ID: 35063965
[TBL] [Abstract] [Full Text] [Related]
19. Clinical impact of npm1-mutant molecular persistence after chemotherapy for acute myeloid leukemia.
Tiong IS; Dillon R; Ivey A; Kuzich JA; Thiagarajah N; Sharplin KM; Kok CH; Tedjaseputra A; Rowland JP; Grove CS; Abro E; Shortt J; Hiwase DK; Bajel A; Potter NE; Smith ML; Hemmaway CJ; Thomas A; Gilkes AF; Russell NH; Wei AH
Blood Adv; 2021 Dec; 5(23):5107-5111. PubMed ID: 34555849
[TBL] [Abstract] [Full Text] [Related]
20. Prognostic significance of long non coding maternally expressed gene 3 in pediatric acute myeloid leukemia.
Xue H; Gao H; Xia H; Li S; Li N; Duan Y; Ren Y; Zhang H; Liu J; Gao W
Medicine (Baltimore); 2021 Sep; 100(35):e26959. PubMed ID: 34477125
[TBL] [Abstract] [Full Text] [Related]
[Next]
